The price of Century Therapeutics Inc (NASDAQ:IPSC) shares last traded on Wall Street fell -2.68% to $0.56.
IPSC stock price is now 6.82% away from the 50-day moving average and -47.87% away from the 200-day moving average. The market capitalization of the company currently stands at $48.15M.
With the price target of $6, Rodman & Renshaw recently initiated with Buy rating for Century Therapeutics Inc (NASDAQ: IPSC). On August 28, 2023, JP Morgan Downgraded its previous ‘Overweight’ rating to ‘Neutral’ on the stock reducing its target price from $28 to quote $5, while ‘Chardan Capital Markets’ rates the stock as ‘Buy’
In other news, Pfeiffenberger Brent, President and CEO sold 29,552 shares of the company’s stock on May 16 ’25. The stock was sold for $16,135 at an average price of $0.55. Upon completion of the transaction, the President and CEO now directly owns 1,682,258 shares in the company, valued at $0.94 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 16 ’25, Officer Pfeiffenberger Brent bought 29,552 shares of the business’s stock. A total of $16,138 was incurred on buying the stock at an average price of $0.55. A total of 52.92% of the company’s stock is owned by insiders.
During the past 12 months, Century Therapeutics Inc has had a low of $0.34 and a high of $3.46. As of last week, the company has a debt-to-equity ratio of 0.22, a current ratio of 11.70, and a quick ratio of 11.70.
The net profit margin was -19.10% and return on equity was -10.49% for IPSC. The company reported revenue of $109.16 million for the quarter, compared to $0.85 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 12667.72 percent.
